Latest Period
Q1 2026
Security Snapshot
Oruka Therapeutics, Inc. - Common Stock, $0.001 par value per share (ORKA) Institutional Ownership
CUSIP: 687604108
13F Institutional Holders and Ownership History from Q3 2024 to Q1 2026
Institutions Reporting
183
Shares (Excl. Options)
52,018,172
Price
$49.05
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, $0.001 par value per share
- Symbol
- ORKA on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 52,018,172
- Total 13F value
- $2,550,553,865
- Portfolio coverage rank
- 0.01%
- Share change
- -1,040,428
- Value change
- +$46,411,000
- Number of holders
- 183
- Shares outstanding
- 50,314,906
- SEC-reported price per share
- $57.98
- Insider filing price
- $57.98
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- ORKA - Oruka Therapeutics, Inc. - Common Stock, $0.001 par value per share is tracked under CUSIP 687604108.
- 183 institutions reported positions in Q1 2026.
- 6 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 144 to 183 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $1,602,044,506 to $2,550,553,865.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 183 institutions filings for Q1 2026.
Security key
687604108
Latest holder period
Q1 2026
13F holders
183
13D/G owners
6
CIK / CUSIP context first
Open Q1 2026 holders
ORKA full holder history
Oruka Therapeutics, Inc. SEC filings
Oruka Therapeutics, Inc. company facts
Oruka Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 687604108:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
6
Security
ORKA
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Fairmount Funds Management LLC | 20% | 0% | $670,272,174 | +$122,739,728 | 13,665,080 | +22% | Fairmount Funds Management LLC | 30 Apr 2026 |
| Venrock Healthcare Capital Partners III, L.P. | 9.9% | -11% | $94,411,973 | +$14,637,703 | 4,909,619 | +18% | Venrock Healthcare Capital Partners III, L.P. | 30 Sep 2025 |
| BlackRock, Inc. | 6.6% | +42% | $96,248,890 | +$29,642,149 | 3,175,483 | +45% | BlackRock, Inc. | 31 Dec 2025 |
| VIKING GLOBAL INVESTORS LP | 5.3% | -3.3% | $130,801,144 | 2,666,690 | 0% | VIKING GLOBAL INVESTORS LP | 31 Mar 2026 | |
| Deep Track Capital, LP | 4.5% | -12% | $65,515,368 | +$8,023,966 | 2,161,510 | +14% | Deep Track Capital, LP | 31 Dec 2025 |
| RTW INVESTMENTS, LP | 4.3% | -18% | $62,382,466 | +$3,409,845 | 2,058,148 | +5.8% | RTW Investments, LP | 31 Dec 2025 |
As of 31 Mar 2026, 183 institutional investors reported holding 52,018,172 shares of Oruka Therapeutics, Inc. - Common Stock, $0.001 par value per share (ORKA). This represents 103% of the company’s total 50,314,906 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
87%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| FMR LLC | 15% | 7,431,403 | +2.3% | 0.02% | $364,510,318 |
| Venrock Adviser, LLC | 8.2% | 4,148,428 | 0% | 7.6% | $203,480,393 |
| Fairmount Funds Management LLC | 7.4% | 3,705,262 | 0% | 13% | $181,743,101 |
| BlackRock, Inc. | 7% | 3,527,087 | -0.35% | 0% | $173,003,617 |
| VIKING GLOBAL INVESTORS LP | 5.3% | 2,666,690 | 0% | 0.37% | $130,801,145 |
| Paradigm Biocapital Advisors LP | 4.6% | 2,320,316 | +36% | 2.3% | $113,811,500 |
| RTW INVESTMENTS, LP | 4.1% | 2,058,148 | 0% | 1% | $100,952,159 |
| Deep Track Capital, LP | 4% | 2,034,203 | -5.9% | 2.1% | $99,777,657 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.7% | 1,859,631 | 0% | 0% | $91,214,901 |
| STATE STREET CORP | 3.2% | 1,613,461 | +17% | 0% | $79,140,262 |
| Remedium Capital Partners, LLC | 3.1% | 1,565,661 | +0.85% | 27% | $76,795,672 |
| PERCEPTIVE ADVISORS LLC | 2.8% | 1,395,501 | -5.5% | 1.4% | $68,449,324 |
| Polar Capital Holdings Plc | 2.1% | 1,047,693 | +7.1% | 0.22% | $51,389,342 |
| CITADEL ADVISORS LLC | 2% | 1,007,537 | +39% | 0.04% | $49,419,690 |
| FRANKLIN RESOURCES INC | 2% | 1,004,056 | +7% | 0.01% | $49,248,948 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.9% | 954,867 | +1.3% | 0% | $46,848,119 |
| MERCER GLOBAL ADVISORS INC /ADV | 1.6% | 802,470 | +7.7% | 0.06% | $39,361,154 |
| Avidity Partners Management LP | 1.5% | 760,424 | +15% | 7.4% | $37,298,797 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1.4% | 727,449 | +12% | 0% | $35,682,000 |
| Woodline Partners LP | 1.1% | 574,882 | +0.06% | 0.11% | $28,197,962 |
| Cormorant Asset Management, LP | 1.1% | 533,340 | 0% | 1.3% | $26,160,327 |
| Bellevue Group AG | 1% | 507,008 | 0.59% | $24,868,742 | |
| Affinity Asset Advisors, LLC | 0.99% | 499,673 | -38% | 1.4% | $24,508,961 |
| Synergy Asset Management, LLC | 0.95% | 476,196 | +3.8% | 2.5% | $23,357,413 |
| SR One Capital Management, LP | 0.86% | 430,330 | 0% | 2.3% | $21,107,686 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
7
Latest
Q1 2026
Rows shown
1-7 of 7
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 52,018,172 | $2,550,553,865 | +$46,411,000 | $49.05 | 183 |
| 2025 Q4 | 52,853,967 | $1,602,044,506 | +$170,793,609 | $30.31 | 144 |
| 2025 Q3 | 45,557,412 | $875,823,009 | +$220,884,566 | $19.23 | 104 |
| 2025 Q2 | 34,429,035 | $385,950,468 | +$30,431,109 | $11.21 | 81 |
| 2025 Q1 | 31,776,517 | $326,087,518 | -$21,453,560 | $10.26 | 70 |
| 2024 Q4 | 31,038,311 | $606,624,310 | +$125,781,752 | $19.39 | 66 |
| 2024 Q3 | 24,559,501 | $604,174,991 | +$603,646,384 | $24.51 | 41 |